



Update regarding Closing of the first stage of the Binding agreement of investment in and acquisition of IOptima

Tel Aviv (February 11, 2018) – Further to BioLight’s announcement dated November 31, 2017 regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOptima (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (“the Acquirer”), and in accordance with the Acquirer’s request, the closing of the first stage of the Agreement is extended until March 31st, 2018.

To BioLight’s best knowledge, the extension of the closing of the first stage of the Agreement is due to delays in timetables that are not exceptional in such transactions and does not result from failure in obtaining or even from difficulties in obtaining the approvals required for the completion of the first stage of the Agreement.

Pending closings pre conditions, the investment in and acquisition in stages of IOptima will be executed in four separate stages, whereby the first stage will include a direct investment into IOptima by Chengdu Kanghong Pharmaceutical Group Co for a total consideration of about US\$7 million at a pre-money valuation of \$30 million, and the following stages will include an acquisition of the remaining IOptima shares from all its other shareholders (including BioLight).